Myomo Valuation Multiples

Myomo Overview

About Myomo

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).

Founded

2004

HQ

Employees

185

Website

myomo.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $42M

EBITDA: ($11M)

EV

$29M

Valuation Multiples

Multiples.vc

Start free trial

Myomo Financials

Myomo reported last 12-month revenue of $42M and negative EBITDA of ($11M).

In the same LTM period, Myomo generated $28M in gross profit, ($11M) in EBITDA losses, and had net loss of ($15M).

Myomo P&L

In the most recent fiscal year, Myomo reported revenue of $41M and EBITDA of ($11M).

Myomo expects next 12-month revenue of XXX and NTM EBITDA of XXX

Myomo Stock Performance

Myomo has current market cap of $29M, and enterprise value of $29M.

Myomo's stock price is $0.75.

Myomo Valuation Multiples

Myomo trades at 0.7x EV/Revenue multiple, and (2.6x) EV/EBITDA.

Myomo Financial Valuation Multiples

As of March 29, 2026, Myomo has market cap of $29M and EV of $29M.

Equity research analysts estimate Myomo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Myomo has a P/E ratio of (1.9x).

Myomo Margins & Growth Rates

Myomo's revenue in the last 12 month grew by 9%.

Myomo's revenue per employee in the last FY averaged $0.2M.

Myomo's rule of 40 is (17%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Myomo's rule of X is (3%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Myomo Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Myomo M&A Activity

Myomo acquired XXX companies to date.

Last acquisition by Myomo was on XXXXXXXX, XXXXX. Myomo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Myomo Investment Activity

Myomo invested in XXX companies to date.

Myomo made its latest investment on XXXXXXXX, XXXXX. Myomo invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).